Citigroup Inc Arbutus Biopharma Corp Put Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	BUY	$3.12 - $4.56 $101,088 - $147,744	32,400 Added 11.37%	317,400 $1.22 Million
Q2 2024 Aug 12, 2024	BUY	$2.52 - $3.63 $126,000 - $181,500	50,000 Added 21.28%	285,000 $880,000
Q1 2024 May 10, 2024	BUY	$2.26 - $2.92 $125,655 - $162,352	55,600 Added 30.99%	235,000 $606,000
Q4 2023 Feb 09, 2024	SELL	$1.69 - $2.54 $25,350 - $38,100	-15,000 Reduced 7.72%	179,400 $448,000
Q2 2023 Aug 10, 2023	BUY	$2.24 - $3.06 $211,456 - $288,864	94,400 Added 94.4%	194,400 $447,000
Q1 2023 May 11, 2023	BUY	$2.23 - $3.1 $223,000 - $310,000	100,000 New	100,000 $303,000

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $477M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.